At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $115.64M, lower than 95% of all stocks globally
- PositionReturn on equity is -192.2%, lower than 95% of its Biotechnology peers (median -21.1%)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
89.01MUSD115.64M · vs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
52-Week Change
-94.63%vs all stocks
Forward Annual Dividend Yield
0.00%vs all stocks
Market Capitalization
89.01MUSD115.64M · vs all stocks (USD)
Enterprise Value
82.17MUSD105.34M · vs all stocks (USD)
Forward P/E
-6.61xvs Biotechnology peers
Price to Book (MRQ)
8.58xvs Biotechnology peers
Enterprise to EBITDA
-12.34xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-42.52%vs Biotechnology peers
Return on Equity (TTM)
-96.56%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Oct 19, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
0.00USDvs all stocks (USD)
Net Income (TTM)
-6.85MUSD-6.48M · vs all stocks (USD)
Operating Cash Flow (TTM)
-5.81MUSD-5.30M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-2.09MUSD-1.53M · vs all stocks (USD)
Forward Annual Dividend Yield
0.00%vs all stocks
Trailing Annual Dividend Rate
0.00USDUpdated Oct 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-7.82MUSDvs all stocks (USD)
Pre-tax Income
-8.98MUSDFY2025 · Dec 31, 2025Net Income
-8.98MUSDFY2025 · Dec 31, 2025EBIT
-7.82MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-6.66MUSDFY2025 · Dec 31, 2025Research & Development
6.27MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
1.55MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-8.98MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-3.86MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
5.14MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-8.98MUSDFY2025 · Dec 31, 2025Stock-based Compensation
4.72MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
398.00KUSDFY2025 · Dec 31, 2025Long-term Debt Payments
0.00USDFY2025 · Dec 31, 2025Net Short-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025Other Financing Charges
-27.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
4.47MUSDFY2025 · Dec 31, 2025Shares Outstanding
49.85MSharesUpdated Oct 19, 2026Float Shares
7.17MSharesUpdated Oct 19, 2026Shares Short
143.34KSharesUpdated Oct 19, 2026Short Ratio
4.57daysvs all stocks
Short % of Shares Outstanding
0.67%vs all stocks
% Held by Insiders
69.92%vs all stocks
% Held by Institutions
4.40%vs all stocks
Total Cash (MRQ)
11.54MUSD3.08M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.2320USDUpdated Oct 19, 2026Total Debt (MRQ)
0.00USDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.00xvs Biotechnology peers
Current Ratio (MRQ)
13.53xvs Biotechnology peers
Book Value per Share (MRQ)
0.2190USDUpdated Oct 19, 2026Total Assets
5.17MUSDvs all stocks (USD)
Total Current Assets
5.17MUSDFY2025 · Dec 31, 2025Total Liabilities
605.00KUSDFY2025 · Dec 31, 2025Total Non-current Assets
0.00USDFY2025 · Dec 31, 2025Total Non-current Liabilities
0.00USDFY2025 · Dec 31, 2025Total Current Liabilities
605.00KUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
5.14MUSDFY2025 · Dec 31, 2025Accounts Payable
470.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
5.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-99.64MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
4.57MUSDvs all stocks (USD)
52-Week Low
1.85USDUpdated Oct 19, 202652-Week High
48.91USDUpdated Oct 19, 202652-Week Change
-94.63%vs all stocks
50-Day MA
2.08USDUpdated Oct 19, 2026200-Day MA
3.75USDUpdated Oct 19, 2026Avg 10-Day Volume
33.89KSharesUpdated Oct 19, 2026Avg 30-Day Volume
30.74KSharesUpdated Oct 19, 2026Diluted EPS (TTM)
-0.1400USDUpdated Oct 19, 2026Other Income / Expense
-1.16MUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Return on equity is -192.2%, lower than 95% of its Biotechnology peers (median -21.1%)Significant
Return on equity: -1.92Industry median: -0.21Industry P5: -1.59Peers compared: 245
Price-to-book is 43.77×, higher than 95% of its Biotechnology peers (median 2.68×)Significant
Price-to-book: 43.77Industry median: 2.68Industry P95: 15.61Peers compared: 245
Debt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.09×)Notable
Debt-to-equity: 0.00Industry median: 0.09Industry P5: 0.00Peers compared: 245
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $115.64M, lower than 95% of all stocks globallySignificant
Market cap (USD): 115,642,703Global P5: 273,689,256.68
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 37,231,057.061
Companies that share the same coordination system — how they create, deliver, or capture value.
Engene Holdings Inc.
Tier 1ProductionApproval-Gated PipelineRule
Faron Pharmaceuticals Oy
Tier 1ProductionApproval-Gated PipelineRuleRisk
Nibec Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Y-Biologics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Anavex Life Sciences Corp.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Cellbion Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Foghorn Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
PepGen Inc.
Tier 1ProductionApproval-Gated PipelineRule
3Billion Inc.
Tier 1ProductionApproval-Gated PipelineSenseMakingRule
Neumora Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking